Search

Your search keyword '"Pella Daniel"' showing total 268 results

Search Constraints

Start Over You searched for: Author "Pella Daniel" Remove constraint Author: "Pella Daniel" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
268 results on '"Pella Daniel"'

Search Results

1. PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation

2. 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)

3. Prevalence of statin intolerance: a meta-analysis

4. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).

5. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

6. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

8. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

9. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

10. Retention projection enables accurate calculation of liquid chromatographic retention times across labs and methods

11. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

12. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

13. The Role of Nutraceuticals in Statin Intolerant Patients

14. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

15. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

16. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

17. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

22. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

23. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

26. Coenzyme [Q.sub.10] and selenium in statin-associated myopathy treatment

30. Metabolic syndrome: a brain disease

32. Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

33. Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

34. The possible role of machine learning in detection of increased cardiovascular risk patients - KSC MR Study (design).

39. Pre‐heart failure at 2D‐ and 3D‐speckle tracking echocardiography: A comprehensive review.

46. An open-source simulator for exploring HPLC theory

48. Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia.

50. The role of physical activity and miRNAs in the vascular aging and cardiac health of dialysis patients.

Catalog

Books, media, physical & digital resources